show that remdesivir may help hospitalized patients recover more quickly, but does not reduce mortality rates. The FDA has approved remdesivir as a treatment for COVID-19 based on the previous positive findings, despite the lack of mortality benefit in the latest data. The drug is now widely used as a treatment option for hospitalized COVID-19 patients, although its effectiveness in reducing mortality remains uncertain. The NIH and WHO studies highlight the importance of ongoing research and evaluation of treatments for COVID-19 to ensure the most effective strategies are being utilized.
Source link
Remdesivir for COVID-19: Where Does It Stand?
